ArticlePloS one2025
M-polynomial driven machine learning models for predicting physicochemical properties of antibiotics.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate prediction of the physicochemical properties of drug compounds is critical for the development of effective and safe antibiotics. In this study, we employ advanced machine learning techniques to address this challenge, using input data that includes M-Polynomials and various physicochemical descriptors. Three models were implemented: basic Support Vector Regression (SVR-Basic), optimized SVR (SVR-Tuned), and Random Forest (RF), trained on known compounds and tested on previously unseen drug samples to evaluate generalization. Model performance was comprehensively assessed using R2, MSE, RMSE, and MAE, alongside detailed error and residual analyses to ensure precision and robustness. Furthermore, residual-based metrics such as the Mean Residual (MR), Standard Deviation of Residuals (Std Residual), and Interquartile Range (IQR) of Residuals were employed to provide complementary insights into prediction bias, consistency, and robustness. By integrating feature importance analysis and ablation studies, the contribution of each molecular descriptor was systematically evaluated, providing deep insights into model stability and the key factors affecting predictive accuracy. Visual comparisons further illustrated the models' behavior on training and test datasets. The results demonstrate that the proposed approach not only improves predictive accuracy compared to prior studies but also offers a robust and reliable framework for real-world drug development. All models were implemented in Python 3.12.7, highlighting the practical applicability of machine learning in pharmaceutical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.